Clinical trials: Pathologic Neovascularization
Macular Edema, Central Serous Chorioretinopathy
Selective Retinal Pigment Epithelium Laser Therapy for Macular Disease of the Retina
Laser photocoagulation of the retina targeting the outer layers is an established therapy for proliferative retinopathy and macular edema from diabetic microangiopathy or retinal vein occlusion, centrals serous retinopathy, and…
- Conditions
- Macular Edema, Central Serous Chorioretinopathy, Retinal Vein Occlusion, Age-related Macular Degeneration
- Trial name
- NCT02088151
- Testing
- Selective retinal pigment epithelium laser therapy using the R:GEN Laser System
- Where
- Switzerland
- Volunteers
- 18 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Graft Versus Host Disease, Acute, Endothelial Dysfunction
Origin of CEC in Patients After Allo-HSCT
We believe that CEC, besides coming from cells shedding from patient vasculature, could partly belong to donor, originating from the cellular graft.
- Conditions
- Graft Versus Host Disease, Acute, Endothelial Dysfunction, Immune Tolerance
- Trial name
- DCEC-PIANO (NCT04038827)
- Testing
- D-CEC counting
- Where
- Italy
- Volunteers
- 15 people
- Sponsor
- Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Retinal Neovascularization, Macular Edema
Longterm Efficiency and Safety of Intravitreal Injections With Bevacizumab in Patients With Neovascularisation or Macular Edema
Although the safety and efficacy of bevacizumab has been established in several phase 3 trials, there is only little documented about the long-term safety and efficacy in the 'real-world practice' in large populations from…
- Trial name
- 2013-005056-15 (NCT03211741)
- Testing
- Bevacizumab Injection [Avastin]
- Where
- Belgium
- Volunteers
- 583 people
- Sponsor
- University Hospital, Ghent
Diabetic Retinopathy, Retinal Neovascularization
Krypton-Argon Regression of Neovascularization Study (KARNS)
To evaluate whether red krypton laser treatment is as effective at causing regression of diabetic disc neovascularization as treatment with the blue-green argon laser, when both lasers are used with identical panretinal…
- Conditions
- Diabetic Retinopathy, Retinal Neovascularization, Diabetes Mellitus
- Trial name
- NCT00000153
- Testing
- Blue-Green Argon Laser Treatment, Red Krypton Laser Treatment
- Sponsor
- National Eye Institute (NEI)
Endometrium, Vascularization
Measuring Endometrial Blood Flow Using Laser Doppler: Acceptability & Reproducibility
35 participants will be recruited from a list of patients who are scheduled, as part of their routine NHS care, to have a clinically-indicated outpatient hysteroscopy for assessment of their uterine cavity.
- Trial name
- EMBeD (NCT04906551)
- Testing
- laser Doppler
- Where
- United Kingdom
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Birmingham Women's and Children's NHS Foundation Trust
Macular Degeneration
Safety and Efficacy Study of Small Interfering Ribonucleic Acid (RNA) Molecule (Cand5) to Treat Wet Age-Related Macular Degeneration
The objective of this study is to evaluate the safety and preliminary efficacy of three doses of Cand5. Cand5, a small interfering RNA molecule that selectively silences the mRNA encoding for VEGF.
- Trial name
- NCT00259753
- Testing
- Bevasiranib
- Where
- 23 sites in United States
- Volunteers
- 120 people
- Sponsor
- OPKO Health, Inc.
Choroidal Neovascularization, Wet Macular Degeneration
Open-Label Study of Intravitreal ICON-1 in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD)
The purpose of this study is to evaluate the safety and effects of repeated intravitreal injections of ICON-1 0.6 mg administered as maintenance therapy or in combination with aflibercept in patients with wet macular degeneration.
- Trial name
- DECO (NCT03452527)
- Testing
- ICON-1, aflibercept
- Where
- 8 sites in United States
- Volunteers
- 15 people
- Sponsor
- Iconic Therapeutics, Inc.
Age-Related Macular Degeneration, Choroidal Neovascularization
Phase 2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Combination With Lucentis® in Patients With Age-Related Macular Degeneration
The purpose of this study is to determine the safety and efficacy of an ocular sirolimus (rapamycin) formulation in combination with Lucentis in patients with sub-foveal choroidal neovascularization secondary to age-related…
- Trial name
- EMERALD (NCT00766337)
- Testing
- Sirolimus in combination with ranibizumab
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Santen Inc.
Neovascular (Wet) Age-related Macular Degeneration
Observation of Treatment Patterns With Lucentis® in Real-life Conditions in All Approved Indications
This study is designed as an observational, non-interventional, multicenter, open label, single arm study in patients being treated with Lucentis® for any approved indication included in the local product posology.
- Trial name
- PACIFIC (NCT04847895)
- Testing
- Lucentis
- Where
- 175 sites in Germany, Netherlands and 1 more
- Volunteers
- 5,500 people
- Sponsor
- Novartis Pharmaceuticals
Pelvic Floor Disorders
Hormonal Status on Blood Flow and Tissue in Pelvic Organ Prolapse
Our primary aim in the current study is to determine important tissue differences, including muscle and connective tissue changes, between postmenopausal women and reproductive age women with pelvic floor dysfunction to help…
- Trial name
- NCT01886794
- Testing
- Postmenopausal, topical vaginal estrogen cream
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- The University of Texas Medical Branch, Galveston
Age-Related Macular Degeneration
Photodynamic Therapy in Occult-Only Lesions (POOL)
Age related macular degeneration is the leading cause of blindness for people over 50 in the western world. Blood vessels which start to grow form a lesion in the back of the eye.
- Trial name
- NCT00135837
- Testing
- Verteporfin for injection
- Where
- Switzerland
- Volunteers
- 202 people
- Sponsor
- Novartis
Retinal Neovascularization
Daily Testing at Home by NV-AMD Subjects With Notal Home OCT.
The purpose of this study is to evaluate the ability of subjects with NV-AMD to perform sequential daily self-imaging of their eyes with the self-operated Notal Home OCT device in their homes for 90 days without on-site…
- Trial name
- NCT04650672
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Notal Vision Inc.
Macular Degeneration
A Study of MSI-1256F (Squalamine Lactate) To Treat "Wet" Age-Related Macular Degeneration
Age-Related Macular Degeneration (AMD) is a degenerative eye disease of the retina that causes a progressive loss of central vision. AMD is the leading cause of legal blindness among adults age 50 or older in the Western world.
- Trial name
- NCT00333476
- Testing
- MSI-1256F (Squalamine Lactate)
- Where
- 9 sites in United States
- Volunteers
- 140 people
- Sponsor
- Genaera Corporation
Polypoidal Choroidal Vasculopathy
Response to Ranibizumab in Polypoidal Choroidal Vasculopathy (PCV)and SNPs
To determine whether complement factor H (CFH) and age-related maculopathy susceptibility 2 (ARMS2) genotypes have a pharmacogenetic effect on the treatment of polypoidal choroidal vasculopathy (PCV) with ranibizumab.
- Trial name
- NCT01271426
- Where
- Japan
- Volunteers
- 74 people
- Sponsor
- Nihon University
Exudative Age-related Macular Degeneration
A Phase II Study of RBM-007 Alone and RBM-007 With Eylea® in Subjects With Wet Age-related Macular Degeneration
This is a multicenter, active-controlled, double masked study assessing the safety, efficacy and durability of four monthly intravitreal (IVT) injections of RBM-007 monotherapy, and four monthly RBM-007 injections in combination…
- Trial name
- TOFU (NCT04200248)
- Testing
- RBM-007 Injectable Solution, Aflibercept
- Where
- 8 sites in United States
- Volunteers
- 94 people
- Sponsor
- Ribomic USA Inc
Corneal Neovascularization
Effectiveness and Safety of Topical Bevacizumab (Avastin) for Treatment of Corneal Neovascularization
Purpose: To determine the efficacy and safety of one commonly used VEGF inhibitor, bevacizumab (Avastin, Genentech), as a topical agent for the treatment of corneal neovascularization.
- Trial name
- NCT00512876
- Testing
- Bevacizumab (Avastin)
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Walter Reed Army Medical Center
Polypoidal Choroidal Vasculopathy
Clinical Implication of Aflibercept in PCV Treatment in China
The purpose of this study is to evaluate the overall treatment characteristics and efficacy of Aflibercept in the treatment of PCV in China through a multicenter, observational, prospective-retrospective study.
- Trial name
- NCT05639660
- Testing
- non-interventional
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Peking Union Medical College Hospital
Retinopathy of Prematurity
Safety and Efficacy of Propranolol 0.2% Eye Drops in Treating Retinopathy of Premature: A Pilot Study (DROP-ROP-0.2%)
The aim of the present study is to evaluate the safety and efficacy of propranolol 0.2% eye drops in treating preterm newborns with a precocious stage of retinopathy of prematurity (ROP).
- Trial name
- NCT02504944
- Testing
- Propranolol 0.2% eye drops
- Where
- 7 sites in Italy
- Volunteers
- 98 people
- Sponsor
- Meyer Children's Hospital IRCCS
Neovascular Age-related Macular Degeneration
An Extension Study Assessing the Efficacy and Safety of Brolucizumab in a Treat-to-Control Regimen in Patients With Neovascular Age-related Macular Degeneration Who Have Completed the CRTH258A2303 (TALON) Study
The purpose of this extension study was to evaluate the efficacy and safety of brolucizumab used in a Treat-to-Control-regimen for treatment of patients with neovascular age-related macular degeneration who have completed the…
- Trial name
- TALON Ext (NCT04597632)
- Testing
- brolucizumab
- Where
- 60 sites in United States, Australia and 14 more
- Volunteers
- 248 people
- Sponsor
- Novartis Pharmaceuticals
Age Related Macular Degeneration
Efficacy and Safety of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)
The study will test if the efficacy and safety of an alternative dosing regimen is as effective as monthly injections.
- Trial name
- EXCITE (NCT00275821)
- Testing
- Ranibizumab 0.3 mg - 3 times monthly, then quarterly, Ranibizumab 0.5 mg - 3 times monthly, then quarterly, Ranibizumab 0.3 mg monthly
- Where
- Switzerland
- Volunteers
- 353 people
- Sponsor
- Novartis